Nobel Prize Winner Dr Gregg Semenza Confirmed to Keynote at IO360º in NYC

Share Article

The Conference Forum announced 2019 Nobel Prize Winner Gregg Semenza, MD, PhD, Johns Hopkins University, as Keynote Speaker of the 8th annual Immuno-Oncology 360º conference, taking place February 16-18, 2022 in NYC. Dr Semenza is Director, Vascular Program, Institute for Cell Engineering, and Professor of Genetic Medicine, at Johns Hopkins.

“Dr Semenza’s pioneering research on molecular mechanisms of oxygen homeostasis and the role for HIF-1a in cancer has transformed our understanding of cancer cell intrinsic mechanisms that lead to tumor growth and progression,” said Priti Hegde, PhD, Chief Scientific Officer, Foundation Medicine.

The Conference Forum announced 2019 Nobel Prize Winner Gregg Semenza, MD, PhD, Johns Hopkins University, as Keynote Speaker of the 8th annual Immuno-Oncology 360º conference, taking place February 16-18, 2022 in NYC. Dr Semenza is Director, Vascular Program, Institute for Cell Engineering, and Professor of Genetic Medicine, at Johns Hopkins.

Dr Semenza received the Nobel Prize in Physiology or Medicine in 2019, for his discovery of hypoxia-inducible factor 1 (HIF-1), how the body’s cells sense and react to low oxygen levels.

“Dr Semenza’s pioneering research on molecular mechanisms of oxygen homeostasis and the role for HIF-1a in cancer has transformed our understanding of cancer cell intrinsic mechanisms that lead to tumor growth and progression,” said Priti Hegde, PhD, Chief Scientific Officer, Foundation Medicine and IO360º 2022 Strategic Advisor. “His recent work on the role of HIF-1a on the TME in promoting immune suppression and resistance to immunotherapies has further emphasized the important role of this biology in promoting immune evasion and cancer progression.”

In discovering this protein, Dr Semenza and other scientists aim to understand how HIF-1 works to develop new treatments for cancer and other diseases. In his keynote, Dr Semenza will be discussing his research and its impact on cancer immunotherapy. His research paves the way for the development of drugs that could kill cancer cells by cutting off the supply of oxygen a tumor needs to grow. HIF inhibitors stimulate anti-tumor immunity and improve the response to immune checkpoint blockade.

“We’re excited for Dr Semenza to share with the IO360º audience how this novel approach to cell death can open new opportunities to improve cancer immunotherapy responses,” said Kate Woda, IO360º Conference Director.

About Immuno-Oncology 360º:
IO360˚is an annual conference in NYC that convenes key stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers. Learn more at http://www.io360summit.com

About the Conference Forum:
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused.

They currently offer conferences for pharma/biotech professionals including R&D leaders, CEOs, business development/licensing, medical affairs/safety, chief patient officers/advocates, clinical innovation champions, investors and drug delivery specialists. The company also publishes six newsletters and produces PharmaTalkRadio and virtual events.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

BreAnna Bugbee
Visit website